Ritu S Baral from 601 110Th St, New York, NY 10025, age 48, Phone: (212) 662-0159

Resumes

Senior Associate

View page

Location:

New York, NY

Industry:

Biotechnology

Work:

Canaccord Genuity Group Inc.
Senior Associate
Jmp Securities 2006 - 2007
Associate
The Trout Group May 2003 - Apr 2006
Senior Associate
Chandler Chicco 2002 - 2002
None
Biosector 2 2002 - 2002
None

Education:

Barnard College 1994 - 1998

Member, Board Of Directors; Chair, Audit Committee

View page

Location:

New York, NY

Industry:

Investment Banking

Work:

Everylife Foundation For Rare Diseases
Member, Board of Directors; Chair, Audit Committee
Cowen and Company
Managing Director, Senior Biotechnology Analyst
Canaccord Genuity Group Inc. Sep 2009 - Jul 2014
Managing Director, Senior Analyst - Biotechnology Equity Research
Pulmonary Fibrosis Foundation Nov 2011 - Dec 2013
Member, Board of Directors
Canaccord Genuity Inc. Aug 2007 - Aug 2009
Senior Associate - Biotechnology Equity Research

Education:

Barnard College 2017
Bachelors, Bachelor of Science Barnard College 1994 - 1998
Bachelors, Bachelor of Science, Biology

Skills:

Equity Research
Biotechnology
Investor Relations
Valuation
Due Diligence
Equities
Financial Modeling
Capital Markets
Investment Banking
Mergers and Acquisitions
Lifesciences
Hedge Funds

Managing Director, Sr. Biotechnology Analyst At Canaccord Genuity

View page

Position:

Member, Board of Directors at Pulmonary Fibrosis Foundation, Managing Director, Senior Analyst - Biotechnology Equity Research at Canaccord Genuity

Location:

Greater New York City Area

Industry:

Investment Banking

Work:

Pulmonary Fibrosis Foundation since Nov 2011
Member, Board of Directors
Canaccord Genuity - New York, NY since Sep 2009
Managing Director, Senior Analyst - Biotechnology Equity Research
Canaccord Genuity Inc. Aug 2007 - Aug 2009
Senior Associate - Biotechnology Equity Research
JMP Securities Apr 2006 - Aug 2007
Associate - Biotechnology Equity Research
The Trout Group May 2003 - Apr 2006
Senior Associate

Education:

Barnard College 1994 - 1998
BS, Biology Holton-Arms

Skills:

Biotechnology
Equity Research
Valuation
Financial Modeling
Lifesciences
Equities
Due Diligence
Investor Relations
Capital Markets
Investment Banking
Mergers & Acquisitions
Hedge Funds

Languages:

German French

News

Sarepta shares are tanking after Duchenne drug setback

View page

We are surprised by the FDAs reasons/concerns and did not anticipate a complete response letter for safety reasons given Exondys 51 has similar backbone chemistry and has never shown any serious safety signal, Cowens Ritu Baral wrote in a note to clients on Tuesday. Whenever the FDA declines to

Date

Aug 20, 2019

Category:

Business

Source:

Google

These Analysts Remain Sidelined on Two Soaring Stocks: PTC Therapeutics, Inc. (PTCT), NVIDIA Corporation (NVDA)

View page

On the heels of the EU conditional approval renewal and with expectation for a new trial to commence come 2017, Cowen analyst Ritu Baral reiterates a Market Perform rating on shares of PTCT without listing a price target.

According to TipRanks, which measures analysts and bloggers success rate based on how their calls perform, four-star analyst Ritu Baral is ranked #671 out of 4,200 analysts. Baral has a 40% success rate and realizes 3.7% in her yearly returns. However, when recommending PTCT, Baral loses 69.5% in

Date

Nov 11, 2016

Category:

Business

Source:

Google

FDA Staff Raise Concern Over Novel Pneumonia Drug

View page

"We think the institutional memory of Ketek will force the division into a highly conservative and defensive stance on solithromycin's safety profile," Ritu Baral, analyst at Cowen and Company, said in a recent research note.

Date

Nov 03, 2016

Category:

Health

Source:

Google

Sarepta's drug approval: The rise of consumer input or the fall of drug standards?

View page

"It sets a precedent for patient advocate involvement and potential power; it sets a precedent for the degree of flexibility that FDA can show if they want to," said Wall Street analyst Ritu Baral. She believes the decision makes rare disease drug development more unpredictable, the report states.

Date

Sep 21, 2016

Category:

Health

Source:

Google

No downpour, but steady drizzle of FDA criticism rains on Kyndrisa parade

View page

Cowen and Co. analyst Ritu Baral wrote in an industry update that a "first blush analysis of the drisa panel briefing documents is more positive for SRPT than we had anticipated. Remarkably, the FDA spends considerable time discussing BMRN's thin dystrophin dataset. We view SRPT's dystrophin dataset

Date

Nov 20, 2015

Category:

Health

Source:

Google

Roche, Boehringer Drugs Wins Approval for Lung Disease

View page

o drugs becausethere havent been any head-to-head trials between them. Sixtypercent of the patients on Boehringers drug experienceddiarrhea as a side effect, a rate that could prove high enoughto relegate the drug to de facto second-line use, Ritu Baral, an analyst at Cowen & Co., said in

Date

Oct 15, 2014

Category:

Health

Source:

Google

Biogen Fourth-Quarter Profit Rises on Multiple Sclerosis Drugs

View page

ontinued U.S. sales growth and a near-term EUlaunch, Ritu Baral, an analyst with Canaccord Genuity, wrotein a research note this week. We see continued Avonex andTysabri long-term value and major potential in Biogenshemophilia franchise with a near-term approval and launchexpected.

Date

Jan 29, 2014

Category:

Business

Source:

Google

Pfizer, Protalix Fail to Win FDA Approval of Cerezyme Rival

View page

Taliglucerase, once approved, may win at least 15 percent of the market led by Genzymes Cerezyme through strong marketing and competitive pricing, said Ritu Baral, an analyst at Canaccord Genuity in New York, in a Feb. 22 note to clients.

Date

Feb 25, 2011

Category:

Health

Source:

Google

Videos & Images

Youtube

Rituharuma timi... Arun Thapa (hemantabaral.co...

Favourite nepalese sentimental song by Arun Thapa.

Category:

Music

Uploaded:

24 May, 2009

Duration:

4m 59s

Ritu S Baral

Ritu Baral Phones & Addresses

Work

Education

Resumes

Resumes

Senior Associate

Member, Board Of Directors; Chair, Audit Committee

Managing Director, Sr. Biotechnology Analyst At Canaccord Genuity